Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
Agonistic 4-1BB antibodies developed for cancer immunotherapy have suffered from either hepatotoxicity or insufficient anti-cancer activity. Here the authors determine the contribution of FcγR binding and agonistic strength to these outcomes, and engineer a 4-1BB antibody with potent anti-tumor effe...
Saved in:
Main Authors: | Xinyue Qi, Fanlin Li, Yi Wu, Chen Cheng, Ping Han, Jieyi Wang, Xuanming Yang |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/00f1cb7bc64c4223a182e521b81631ef |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ecto-ADP-ribosyltransferase ARTC2.1 functionally modulates FcγR1 and FcγR2B on murine microglia
by: Björn Rissiek, et al.
Published: (2017) -
Fc γ receptor IIIB (FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children.
by: Bright Adu, et al.
Published: (2012) -
Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies
by: E. R. Job, et al.
Published: (2019) -
Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
by: Tadashi Maemura, et al.
Published: (2021) -
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
by: Marta Compte, et al.
Published: (2018)